Legumain-IN-2
Legumain-IN-2 is a selective legumain inhibitor with a human legumain IC50 of 0.9 nM. Legumain-IN-2 can be used for the research of breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 1609690-02-9
- Formula: C25H28N4O5
- Molecular Weight:464.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
100 nM
Compound: 7u
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 24775305] |
| T47D | IC50 |
100 nM
Compound: 7u
|
Cytotoxicity against human T47D cells
Cytotoxicity against human T47D cells
|
[PMID: 24775305] |
In Vitro
Legumain-IN-2 (Compound 7u) potently inhibits recombinant human Legumain with an IC50 of 0.9 nM[1].
Legumain-IN-2 (30 μM) is highly selective for Legumain, showing minimal to moderate inhibition of other tested cysteine proteases[1].
Legumain-IN-2 (30 μM; 120 h) reduces cell count by >70% in MCF7 and T47D breast cancer cells, but has no effect on MCF10a and HME-1 normal breast cell viability under the same conditions[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human breast cancer cell lines MCF7, T47D; normal human breast cell lines MCF10a, HME-1
-
Concentration:30 μM
-
Incubation Time:120 h
-
Result:Reduced cell count by >70% in MCF7 and T47D breast cancer cells compared to vehicle control.
Had no impact on cell viability in MCF10a and HME-1 normal breast cell lines.
Chemical Information
-
CAS No. 1609690-02-9
-
Molecular Weight 464.51
-
Formula C25H28N4O5
-
SMILES
NC(C[C@@H](C#N)NC([C@H]1N(CCC1)C(OCC2=CC=C(C3=CC(OCC)=CC=C3)C=C2)=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Legumain-IN-2 Related Classifications
HY-183119 Related Classifications
Powered by Bioz